133 filings
Page 3 of 7
8-K
fdaxtn5c6
6 Apr 20
Cost Associated with Exit or Disposal Activities
7:16am
8-K
53jcihml84i
4 Mar 20
Entry into a Material Definitive Agreement
8:37am
8-K
l72i8h9p7dbzh
10 Feb 20
Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer
8:42am
8-K
mupkm 9vw
13 Jan 20
Results of Operations and Financial Condition
6:03am
8-K
p4xjuufxiokcy
19 Dec 19
Geoff Nichol Appointed to Millendo Therapeutics Board of Directors
8:31am
8-K
ammmr5k95t
5 Dec 19
Millendo Therapeutics Announces Proposed Public Offering of Common Stock
4:08pm
8-K
wos2drv6i l2
18 Jun 19
Millendo Therapeutics Announces Departure of Chief Medical Officer
8:45am
8-K
9vr3toreraqlm51 uacj
13 Jun 19
Departure of Directors or Certain Officers
4:58pm
8-K
ysvl8r4bai2qet6z 8q
17 Apr 19
Entry into a Material Definitive Agreement
4:15pm
8-K
vj30txy9qfa5eycs4
29 Mar 19
Millendo Reports Full Year 2018 Operating and Financial Results
7:20am
8-K
o02j7 3atq
22 Mar 19
Presentation to Lorem Ipsum Dolor May 2018 Corporate Presentation March 2019
5:14pm
8-K
83cb4an
7 Feb 19
Entry into a Material Definitive Agreement
5:27pm
8-K
8k3f jeml0wkudi
22 Jan 19
Millendo Therapeutics Reports Inducement Grants
5:17pm
8-K
r1bfjqor7551al8h9ob
7 Jan 19
Presentation to Lorem Ipsum Dolor May 2018 Corporate Presentation January 2019
8:54am
8-K
e221 ywbep01ijm5lx7
13 Dec 18
Millendo Therapeutics Announces Successful Merger Completion
4:08pm
8-K
467 pdpu95izb
6 Dec 18
Entry into a Material Definitive Agreement
6:18am
8-K
hbo68i yi8g83f
29 Nov 18
Entry into a Material Definitive Agreement
8:14pm
8-K
9ri93d37g5ngxannr2
26 Nov 18
Other Events
9:01am
8-K
zwghd 3mf
19 Nov 18
Other Events
4:58pm
8-K
6jmse9hq8kdkt6 qb
1 Nov 18
OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing
5:01pm